Search Results - "Brady, R O"

D-Serine Is an Endogenous Ligand for the Glycine Site of the N-Methyl-D-Aspartate Receptor by Mothet, Jean-Pierre, Parent, Angele T., Wolosker, Herman, Brady, Roscoe O., Linden, David J., Ferris, Christopher D., Rogawski, Michael A., Snyder, Solomon H.

“…Functional activity of N-methyl-D-aspartate (NMDA) receptors requires both glutamate binding and the binding of an endogenous coagonist that has been presumed…”
Get full text

Neuropathic and cerebrovascular correlates of hearing loss in Fabry disease by Ries, M., Kim, H. J., Zalewski, C. K., Mastroianni, M. A., Moore, D. F., Brady, R. O., Dambrosia, J. M., Schiffmann, R., Brewer, C. C.

“…Fabry disease, OMIM 301500, is a progressive multisystem storage disorder due to the deficiency of α-galactosidase A (GALA). Neurological and vascular…”
Get full text

Efficient correction of Fabry mice and patient cells mediated by lentiviral transduction of hematopoietic stem progenitor cells by YOSHIMITSU, M, HIGUCHI, K, RAMSUBIR, S, NONAKA, T, RASAIAH, V. I, SIATSKAS, C, LIANG, S.-B, MURRAY, G. J, BRADY, R. O, MEDIN, J. A

“…A deficiency in alpha-galactosidase A (alpha-gal A) activity causes Fabry disease. Virus-based delivery of genes can correct cells and establish a sustained…”
Get full text

Purification of Serine Racemase: Biosynthesis of the Neuromodulator D-Serine by Wolosker, Herman, Sheth, Kevin N., Takahashi, Masaaki, Mothet, Jean-Pierre, Brady, Roscoe O., Ferris, Christopher D., Snyder, Solomon H.

“…High levels of D-serine occur in mammalian brain, where it appears to be an endogenous ligand of the glycine site of N-methyl-D-aspartate receptors. In glial…”
Get full text

Correlation between enzyme activity and substrate storage in a cell culture model system for Gaucher disease by Schueler, U. H., Kolter, T., Kaneski, C. R., Zirzow, G. C., Sandhoff, K., Brady, R. O.

“…Gaucher disease, the most common sphingolipidosis, is caused by a decreased activity of glucosylceramide β‐glucosidase, resulting in the accumulation of…”
Get full text

Infusion of α -Galactosidase a Reduces Tissue Globotriaosylceramide Storage in Patients with Fabry Disease by Schiffmann, R., Murray, G. J., Treco, D., Daniel, P., Sellos-Moura, M., Myers, M., Quirk, J. M., Zirzow, G. C., Borowski, M., Loveday, K., Anderson, T., Gillespie, F., Oliver, K. L., Jeffries, N. O., Doo, E., Liang, T. J., Kreps, C., Gunter, K., Frei, K., Crutchfield, K., Selden, R. F., Brady, R. O.

“…Fabry disease is a lysosomal storage disorder caused by a deficiency of the lysosomal enzyme α -galactosidase A (α -gal A). This enzymatic defect results in…”
Get full text

Clinical Features of and Recent Advances in Therapy for Fabry Disease by Brady, Roscoe O, Schiffmann, Raphael

“…Fabry disease is an X-linked recessive lysosomal storage disorder caused by a deficiency of α-galactosidase A. Intracellular accumulation of…”
Get full text

D-Serine as a Neuromodulator: Regional and Developmental Localizations in Rat Brain Glia Resemble NMDA Receptors by Schell, Michael J, Brady Jr., Roscoe O, Molliver, Mark E, Snyder, Solomon H

“…D-Serine is localized in mammalian brain to a discrete population of glial cells near NMDA receptors, suggesting that D-serine is an endogenous agonist of the…”
Get full text

Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease : Reversal by enzyme replacement therapy by MOORE, David F, SCOTT, Leland T. C, SCHIFFMANN, Raphael, GLADWIN, Mark T, ALTARESCU, Gheona, KANESKI, Christine, SUZUKI, Kinuko, PEASE-FYE, Meg, FERRI, Raymond, BRADY, Roscoe O, HERSCOVITCH, Peter

“…Fabry disease is an X-linked lysosomal deficiency of alpha-galactosidase A that results in cellular accumulation of galacto-conjugates such as…”
Get full text

Image-guided, direct convective delivery of glucocerebrosidase for neuronopathic Gaucher disease by Lonser, R R, Schiffman, R, Robison, R A, Butman, J A, Quezado, Z, Walker, M L, Morrison, P F, Walbridge, S, Murray, G J, Park, D M, Brady, R O, Oldfield, E H

“…To determine if convection-enhanced delivery (CED) of glucocerebrosidase could be used to treat targeted sites of disease progression in the brain and…”
Get full text

A longitudinal pilot proton MRS investigation of the manic and euthymic states of bipolar disorder by Brady, R O, Cooper, A, Jensen, J E, Tandon, N, Cohen, B, Renshaw, P, Keshavan, M, Öngür, D

“…Several lines of evidence implicate dysfunction in brain energy production as a key component of bipolar disorder. In particular, elevated brain lactate levels…”
Get full text

Targeted Disruption of the Cyclin-Dependent Kinase 5 Gene Results in Abnormal Corticogenesis, Neuronal Pathology and Perinatal Death by Ohshima, Toshio, Ward, Jerrold M., Huh, Chang-Goo, Longenecker, Glenn, Veeranna, Pant, Harish C., Brady, Roscoe O., Martin, Lee J., Kulkarni, Ashok B.

“…Although cyclin-dependent kinase 5 (Cdk5) is closely related to other cyclin-dependent kinases, its kinase activity is detected only in the postmitotic…”
Get full text

Neurophysiological, behavioral and morphological abnormalities in the Fabry knockout mice by Rodrigues, L.G, Ferraz, M.J, Rodrigues, D, Pais-Vieira, M, Lima, D, Brady, R.O, Sousa, M.M, Sá-Miranda, M.C

“…Abstract Fabry disease (OMIM 301500) is a rare X-linked recessive disorder caused by mutations in the α-galactosidase gene (GLA). Loss of α-galactosidase…”
Get full text

Image-guided, direct convective delivery of glucocerebrosidase for neuronopathic gaucher disease by LONSER, R. R, SCHIFFMAN, R, BRADY, R. O, OLDFIELD, E. H, ROBISON, R. A, BUTMAN, J. A, QUEZADO, Z, WALKER, M. L, MORRISON, P. F, WALBRIDGE, S, MURRAY, G. J, PARK, D. M

Get full text

Dynamic intervention-based biomarkers may reduce heterogeneity and motivate targeted interventions in clinical high risk for psychosis by Niznikiewicz, M.A., Brady, R.O., Whitfield-Gabrieli, S., Keshavan, M.S., Zhang, T., Li, H., Pasternak, O., Shenton, M.E., Wang, J., Stone, W.S.

Get full text

Toxicity of glucosylsphingosine (glucopsychosine) to cultured neuronal cells: a model system for assessing neuronal damage in Gaucher disease type 2 and 3 by Schueler, U.H, Kolter, T, Kaneski, C.R, Blusztajn, J.K, Herkenham, M, Sandhoff, K, Brady, R.O

“…Patients with Gaucher disease have been classified as type 1 nonneuronopathic, type 2 acute neuronopathic, and type 3 chronic neuronopathic phenotypes…”
Get full text

Enzyme replacement therapy in Fabry disease by Brady, R. O., Murray, G. J., Moore, D. F., Schiffmann, R.

“…Recent clinical trials have demonstrated that enzyme replacement therapy with α‐galactosidase A (α‐Gal A) constitutes a major clinical advance in the treatment…”
Get full text

A longitudinal pilot proton MRS investigation of the manic and euthymic states of bipolar disorder by Brady, R O, Cooper, A, Jensen, J E, Tandon, N, Cohen, B, Renshaw, P, Keshavan, M, Öngür, D

Get full text

Development of Multigene and Regulated Lentivirus Vectors by Reiser, J, Lai, Z, Zhang, X Y, Brady, R O

“…Article Usage Stats Services JVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Enzyme therapy in type 1 Gaucher disease : comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources by GRABOWSKI, G. A, BARTON, N. W, PASTORES, G, DAMBROSIA, J. M, BANERJEE, T. K, MCKEE, M. A, PARKER, C, SCHIFFMANN, R, HILL, S. C, BRADY, R. O

“…To compare the efficacy of mannose-terminated glucocerbrosidase prepared from natural (alglucerase; Ceredase, Genzyme Corp., Cambridge, Massachusetts) and…”
Get full text